Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT162b2 2025/2026 Variant-Adapted Vaccine in Higher-Risk and Older Participants
NCT07069309Phase 3Completed
- Sponsor
- BioNTech SE
- Start
- Jul 2025
- Primary completion
- May 2026
- Modality
- Vaccines & Immunotherapeutics, Lipid-based Nanoparticles, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by BioNTech SE. Started Jul 2025; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07069309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07069309.